Antiviral effects of a RIG-I agonist (RIG101) against human rhinovirus in mice and differentiated bronchial epithelium from asthmatics - Amsterdam 2025

Charting new avenues: emerging insights and future therapies in airway diseases

Chair(s): Reshed Abohalaka, Lena Uller

Session type: Oral presentation

Antiviral effects of a RIG-I agonist (RIG101) against human rhinovirus in mice and differentiated bronchial epithelium from asthmatics

Hugo Ombredane

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Amlitelimab phase 2 clinical trial results in patients with moderate-to-severe asthma

Praveen Akuthota

Replay

Poster

Abstract

Slides

Airway lumen patency improvements from baseline to 6 months in patients with emphysema-related hyperinflation treated with a novel self-expanding nitinol airway scaffold

Theresa Klemm

Replay

Poster

Abstract

Slides

IL-5 CAR-T cell therapy: a transformative approach for eosinophil-driven respiratory diseases

Songmin Ying

Replay

Poster

Abstract

Slides

Autologous transplantation of airway basal stem cells in COPD patients: A randomized, single-blind, placebo-controlled phase 2 trial

Wei Zuo

Replay

Abstract

Slides

The effects of a novel macrolide glasmacinal (EP395) on alveolar macrophage phenotype and phagocytosis in COPD

Simon Lea

Replay

Abstract

Slides

Differentially-Expressed Genes (DEGs) related to anti-IL5/IL5R? therapeutic response in Severe Eosinophilic Asthma

Katie Raby

Replay

Poster

Abstract

Slides

Antiviral effects of a RIG-I agonist (RIG101) against human rhinovirus in mice and differentiated bronchial epithelium from asthmatics

Hugo Ombredane

Replay

Poster

Abstract

Slides

Morphine or Fentanyl for Refractory Dyspnea in COPD: a multicenter, cross-over RCT

Marlies Van Dijk

Replay

Poster

Abstract

Slides

ETH47 is a novel mRNA drug candidate for the prevention of asthma exacerbations

Thomas Langenickel

Replay

Poster

Abstract

Slides

AI-Driven Identification of High-Risk COPD Patients for Biologic Therapy: Pathway Development Opportunities

Chris Carlin

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}